酪氨酸激酶抑制剂治疗晚期肾癌的研究现状

发布时间：2018-06-25 08:06

本文选题：酪氨酸激酶抑制剂 + 晚期肾癌　；参考：《重庆医科大学》2014年硕士论文

【摘要】：肾癌是来源于肾实质泌尿小管上皮系统的恶性肿瘤,是泌尿系统的常见病和高发病，在人类恶性肿瘤中肾癌的发病率占有很高的比重,约占成人恶性肿瘤的2%～3%，占成人肾脏恶性肿瘤的80%～90%。肾脏丰富的血供决定了肾癌的早期高转移性，，约25%的肾癌病人存在肿瘤转移,很大一部分患者在初诊时即发现肿瘤转移，统计资料显示，死于肾癌的患者数目逐年增加。故而晚期肾癌的治疗对于患者的预后及生存质量提高均具有重要意义，近年来，随着对肾癌生物学及分子发病机制的深入了解,尤其是分子信号通路方面研究的不断深入,靶向治疗在晚期肾癌治疗方面已显现出明显优势，其中各种酪氨酸激酶抑制剂更是广泛的应用于临床上肾癌的治疗，有效地改善了晚期肾癌患者的预后。酪氨酸激酶抑制剂是一种酶受体蛋白，它可以催化腺嘌呤核苷三磷酸里面的磷酸盐向多肽里面的酪氨酸转运，从而有效的抑制肿瘤的增殖、血管生成和侵袭。本文将对酪氨酸激酶抑制剂治疗晚期肾癌的治疗原理，各种酪氨酸激酶抑制剂的治疗晚期肾癌的治疗效果和安全性进行阐述，探讨酪氨酸激酶抑制剂治疗晚期肾癌的研究现状，从而更好的帮助临床医生制定治疗方案。
[Abstract]:Renal cell carcinoma is a malignant tumor derived from the renal parenchymal urothelial system. It is a common and high incidence disease of the urinary system. It accounts for 2% of adult malignant tumors and 80% of adult renal malignancies. The abundant blood supply of kidney determines the early high metastasis of renal cell carcinoma. About 25% of renal cancer patients have tumor metastasis. A large number of patients found tumor metastasis at the first visit. Statistics show that the number of patients who died of renal carcinoma increased year by year. Therefore, the treatment of advanced renal cell carcinoma plays an important role in improving the prognosis and quality of life of patients. In recent years, with the in-depth understanding of the biology and molecular pathogenesis of renal cell carcinoma, especially the study of molecular signal pathway, Targeted therapy has shown obvious advantages in the treatment of advanced renal cell carcinoma, among which various tyrosine kinase inhibitors have been widely used in clinical treatment of renal cell carcinoma, which can effectively improve the prognosis of patients with advanced renal cell carcinoma. Tyrosine kinase inhibitor is an enzyme receptor protein that catalyzes the transport of phosphate from adenosine triphosphate to tyrosine in polypeptides, which effectively inhibits tumor proliferation, angiogenesis and invasion. In this paper, the principle of tyrosine kinase inhibitor in the treatment of advanced renal cell carcinoma, the therapeutic efficacy and safety of various tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma were reviewed, and the current research status of tyrosine kinase inhibitor in the treatment of advanced renal cell carcinoma was discussed. In order to better help clinicians to develop treatment plans.
【学位授予单位】：重庆医科大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R737.11

【参考文献】